Skip to main content
Explore URMC

URMC Logo

menu

Paul M. Barr, M.D.

Cancer

Publications

Showing all 69 journal articles & 2 books available

Journal Articles

7/11/2017
Williams AM, Baran AM, Meacham PJ, Feldman MM, Valencia HE, Newsom-Stewart C, Gupta N, Janelsins MC, Barr PM, Zent CS. "Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies." Leukemia & lymphoma.. 2017 Jul 11; :1-8. Epub 2017 Jul 11.

7/2017
Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM. "Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib." British journal of haematology.. 2017 Jul 0; 178(2):286-291. Epub 2017 Apr 10.

6/8/2017
Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. "Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL." Leukemia.. 2017 Jun 8; Epub 2017 Jun 08.

6/1/2017
Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, Salles GA, Friedberg JW. "Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy." Blood.. 2017 Jun 1; 129(22):3037-3039. Epub 2017 Mar 21.

6/2017
Martin P, Barr PM, James L, Pathak A, Kahl B. "Long-term safety experience with bendamustine for injection in a real-world setting." Expert opinion on drug safety.. 2017 Jun 0; 16(6):647-650. Epub 2017 Apr 17.

5/11/2017
Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC. "Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL." Blood.. 2017 May 11; 129(19):2612-2615. Epub 2017 Apr 03.

5/6/2017
Rowswell-Turner RB, Barr PM. "Treatment of chronic lymphocytic leukemia in older adults." Journal of geriatric oncology.. 2017 May 6; Epub 2017 May 06.

4/20/2017
Barr PM. "Efficacy in the margins of NHL with ibrutinib." Blood.. 2017 Apr 20; 129(16):2207-2208.

4/2017
Reagan PM, Barr PM. "Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve." The Lancet. Haematology.. 2017 Apr 0; 4(4):e152-e153. Epub 2017 Mar 15.

3/2017
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. "RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106." British journal of haematology.. 2017 Mar 0; 176(5):759-769. Epub 2016 Dec 19.

3/2017
Hunter BD, Herr M, Meacham PJ, Barlaskar F, Evans AG, Burack WR, Liesveld JL, Becker MW, Milner LA, Constine LS, Dhakal S, Barr PM, Friedberg JW, Casulo C. "Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era." Clinical lymphoma, myeloma & leukemia.. 2017 Mar 0; 17(3):145-151. Epub 2016 Nov 23.

3/2017
Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM. "Recommendations for Clinical Trial Development in Follicular Lymphoma." Journal of the National Cancer Institute.. 2017 Mar 0; 109(3)Epub 2016 Dec 31.

1/27/2017
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. "Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients." Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Jan 27; Epub 2017 Jan 27.

1/25/2017
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. "Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients." Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Jan 25; Epub 2017 Jan 25.

1/2017
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. "Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients." Annals of oncology : official journal of the European Society for Medical Oncology. 2017 28(5):1050-1056.

2017
Jaffe ES, Barr PM, Smith SM. "Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice." American Society of Clinical Oncology educational book. 2017 37:535-546.

12/8/2016
Barr PM. "Deregulation of NF-?B, ie, a useful PMBL marker." Blood.. 2016 Dec 8; 128(23):2591-2592.

11/3/2016
Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. "Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience." Blood.. 2016 Nov 3; 128(18):2199-2205. Epub 2016 Sep 06.

11/2016
Reid RM, Baran A, Friedberg JW, Phillips GL, Liesveld JL, Becker MW, Wedow L, Barr PM, Milner LA. "Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective." Cancer medicine. 2016 Nov 0; 5(11):3059-3067. Epub 2016 Oct 03.

10/1/2016
Youn P, Cummings MA, Dhakal S, Burack WR, Casulo C, Barr PM, Friedberg JW, Constine LS. "Prognostic Impact of Cell of Origin in Limited-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP With or Without Radiation Therapy." International journal of radiation oncology, biology, physics.. 2016 Oct 1; 96(2S):E495.

9/15/2016
Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. "Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma." Blood.. 2016 Sep 15; 128(11):1458-64. Epub 2016 Jul 25.

9/2016
Herr MM, Mohile NA, Barr PM, van Wijngaarden E, Brown EB, Rich DQ. "Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era." Clinical lymphoma, myeloma & leukemia.. 2016 Sep 0; 16(9):e123-e127. Epub 2016 Jun 08.

8/25/2016
Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O. "Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy." Blood.. 2016 Aug 25; 128(8):1112-20. Epub 2016 Jul 14.

7/2016
Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ. "Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia." Haematologica.. 2016 Jul 0; 101(7):e295-8. Epub 2016 May 05.

6/10/2016
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. "US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 Jun 10; 34(17):2020-7. Epub 2016 Apr 11.

6/2016
Reagan PM, Baran A, Kelly JL, Barr PM, Casulo C, Chengazi VU, Friedberg JW. "Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma." Clinical lymphoma, myeloma & leukemia.. 2016 Jun 0; 16(6):322-328.e2. Epub 2016 Apr 02.

5/19/2016
Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O'Brien SM, Liem AK, McIntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW. "Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL." Blood.. 2016 May 19; 127(20):2411-5. Epub 2016 Mar 11.

3/24/2016
Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. "Postibrutinib outcomes in patients with mantle cell lymphoma." Blood.. 2016 Mar 24; 127(12):1559-63. Epub 2016 Jan 13.

2016
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW. "Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas." Leukemia & lymphoma.. 2016 57(3):635-43. Epub 2015 Oct 12.

12/17/2015
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ, . "Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia." The New England journal of medicine.. 2015 Dec 17; 373(25):2425-37. Epub 2015 Dec 06.

12/2015
Choudary I, Barr PM, Friedberg J. "Recent advances in the development of Aurora kinases inhibitors in hematological malignancies." Therapeutic advances in hematology.. 2015 Dec 0; 6(6):282-94.

8/2015
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. "Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma." Nature medicine.. 2015 Aug 0; 21(8):922-6. Epub 2015 Jul 20.

7/20/2015
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. "Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 Jul 20; 33(21):2399-404. Epub 2015 Jun 15.

5/7/2015
Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. "The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia." Blood.. 2015 May 7; 125(19):2915-22. Epub 2015 Mar 09.

3/2015
Barr PM. "Rituximab maintenance in follicular lymphoma." Clinical advances in hematology & oncology : H&O.. 2015 Mar 0; 13(3):158-61.

2/2015
Hutchinson K, Jahangiri S, Calvi LM, Barr P, Friedberg JW, Kelly JL. "Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma." Leukemia & lymphoma.. 2015 Feb 0; 56(2):508-11. Epub 2014 Jul 15.

12/2014
Barr PM, Zent CS. "Infection in chronic lymphocytic leukemia: parsimony has its limits." Leukemia & lymphoma.. 2014 Dec 0; 55(12):2683-4. Epub 2014 May 16.

9/2014
Jahangiri S, Barr P, Friedberg J. "Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma." Expert opinion on emerging drugs.. 2014 Sep 0; 19(3):367-83. Epub 2014 Jun 24.

8/21/2014
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM. "Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma." Blood.. 2014 Aug 21; 124(8):1259-65. Epub 2014 Jul 11.

8/2014
Barr PM. "Maintenance rituximab should be considered for patients with follicular lymphoma." Clinical advances in hematology & oncology : H&O.. 2014 Aug 0; 12(8):541-3.

7/17/2014
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P, . "Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia." The New England journal of medicine.. 2014 Jul 17; 371(3):213-23. Epub 2014 May 31.

7/2014
Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI. "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma." Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jul 0; 25(7):1449.

6/2014
Barr PM, Zent CS. "The ABC of chronic lymphocytic leukemia: etiology of cytopenias is important in staging and management." Leukemia & lymphoma.. 2014 Jun 0; 55(6):1219-20. Epub 2013 Nov 01.

3/1/2014
Cleary JM, Rodig S, Barr PM, Shinagare AB, Clark JW, Shapiro GI, Armand P. "Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma." Journal of the National Comprehensive Cancer Network : JNCCN.. 2014 Mar 1; 12(3):323-6; quiz 326.

12/2013
Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI. "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma." Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Dec 0; 24(12):3076-81. Epub 2013 Oct 20.

10/2013
Barr PM. "Flavopiridol: Judged by the company one keeps." Leukemia research.. 2013 Oct 0; 37(10):1187-8. Epub 2013 Jul 08.

8/2013
Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW. "Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia." Leukemia.. 2013 Aug 0; 27(8):1769-73. Epub 2013 Feb 06.

2/2013
Barr PM. "Fffuse large B-cell lymphoma in the very elderly: the case for refining our clinical trials." Oncology.. 2013 Feb 0; 27(2):140, 142.

12/2012
Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore P, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Cooley T, Henry DH, Barr P, Noy A. "Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium." Leukemia & lymphoma.. 2012 Dec 0; 53(12):2383-9. Epub 2012 Jul 09.

7/2012
Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ, Margevicius S, Fu P, van Heeckeren W, Lazarus HM, Cooper BW, Gerson SL, Barr P, Tse WW, Curtis C, Fanning LR, Creger RJ, Carlson-Barko JM, Laughlin MJ. "Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies." Bone marrow transplantation.. 2012 Jul 0; 47(7):924-33. Epub 2011 Oct 17.

6/2012
Noel MS, Friedberg JW, Barr PM. "Novel agents in mantle cell lymphoma." Best practice & research. Clinical haematology.. 2012 Jun 0; 25(2):191-200. Epub 2012 Apr 30.

3/2012
Barr PM, Wei C, Roger J, Schaefer-Cutillo J, Kelly JL, Rosenberg AF, Jung J, Sanz I, Friedberg JW. "Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion." Clinical immunology : the official journal of the Clinical Immunology Society.. 2012 Mar 0; 142(3):237-42. Epub 2012 Jan 05.

2012
Caimi PF, Barr PM, Berger NA, Lazarus HM. "Non-Hodgkin's Lymphoma in the Elderly". Drugs & Aging. 2012; 27(3): 211-238.

2012
Noel, MS; Friedberg, JW; Barr, PM;. "Novel agents in mantle cell lymphoma". Best Practices & Resaerch Clinical Haematology. 2012; 25(2): 191-200.

11/2011
Carter SJ, Bernstein SH, Friedberg JW, Barr PM. "Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma." Leukemia research.. 2011 Nov 0; 35(11):e223-4. Epub 2011 Aug 06.

7/2011
Lazarus HM, Sommers SR, Arfons LM, Fu P, Ataergin SA, Kaye NM, Liu F, Kindwall-Keller TL, Cooper BW, Laughlin MJ, Creger RJ, Barr PM, Gerson SL, Kaplan D. "Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2011 Jul 0; 17(7):970-8. Epub 2011 Apr 11.

7/2011
Barr PM, Friedberg JW. "Getting to the heart of the problem in treating diffuse large B-cell lymphoma." Leukemia & lymphoma.. 2011 Jul 0; 52(7):1166-7. Epub 2011 May 25.

6/2011
Dao H, Barr PM, Honda K. "Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox." Journal of the American Academy of Dermatology.. 2011 Jun 0; 64(6):e123-5.

9/2010
Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, Distelhorst CW. "Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia." Cell death and differentiation.. 2010 Sep 0; 17(9):1381-91. Epub 2010 Mar 19.

3/1/2010
Caimi PF, Barr PM, Berger NA, Lazarus HM. "Non-Hodgkin's lymphoma in the elderly." Drugs & aging.. 2010 Mar 1; 27(3):211-38.

3/2010
Kaplan D, Meyerson HJ, Li X, Drasny C, Liu F, Costaldi M, Barr P, Lazarus HM. "Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL." Cytometry. Part B, Clinical cytometry.. 2010 Mar 0; 78(2):115-22.

10/2009
Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, Bahlis NJ, Snell MR, Dowlati A, Cooper BW. "Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma." British journal of haematology.. 2009 Oct 0; 147(1):89-96. Epub 2009 Jun 29.

8/2009
Barr PM, Lazarus HM, Cooper BW, Schluchter MD, Panneerselvam A, Jacobberger JW, Hsu JW, Janakiraman N, Simic A, Dowlati A, Remick SC. "Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant." American journal of hematology.. 2009 Aug 0; 84(8):484-7.

6/2009
Rong YP, Barr P, Yee VC, Distelhorst CW. "Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor." Biochimica et biophysica acta.. 2009 Jun 0; 1793(6):971-8. Epub 2008 Nov 12.

9/2008
Barr PM, Lazarus HM. "Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation." Current opinion in oncology.. 2008 Sep 0; 20(5):502-8.

12/2007
Barr P, Fisher R, Friedberg J. "The role of bortezomib in the treatment of lymphoma." Cancer investigation.. 2007 Dec 0; 25(8):766-75.

10/2007
Barr P, Fu P, Lazarus H, Kane D, Meyerson H, Hartman P, Reyes R, Creger R, Stear K, Laughlin M, Tse W, Cooper B. "Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia." Leukemia & lymphoma.. 2007 Oct 0; 48(10):1940-9.

7/18/1997
Malinowski MN, Cannady SB, Schmit KV, Barr PM, Schrock JW, Wilson DF. "Adenosine depresses transmitter release but is not the basis for 'tetanic fade' at the neuromuscular junction of the rat." Neuroscience letters.. 1997 Jul 18; 230(2):81-4.

0
Barr PM, Zent CS. "The ABC of chronic lymphocytic leukemia: Etiology of cytopenias is important in staging and management". Leukemia Lymphoma [EPub in press]. .

Books & Chapters

2012
Chapter Title: Rare B Cell Lymphoproliferative Disorders
Book Title: Textbook of Uncommon Cancers
Author List: Barr PM and Friedberg JW
Published By: Wiley-Blackwell2012 in Oxford, England

2010
Chapter Title: Pharmacology of Acute Lymphoblastic Leukemia Therapy
Book Title: Adult Acute Lymphocytic Leukemia: Biology and Treatment
Author List: Barr PM, Creger RJ, Berger NA
Published By: Humana Press2010